

Date: 11th October, 2021

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Tower, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its New Injectable Facility (F-3) at Karakhadi

Ref.: Our earlier intimation dated 8th February, 2021 - USFDA Inspection at Alembic Pharmaceuticals New Injectable Facility (F-3) at Karakhadi

This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our New Injectable Facility (F-3) at Karakhadi during the period from 28th January, 2021 to 6th February, 2021, indicating that the USFDA finds our responses to their observations to be adequate. USFDA has also indicated that a compliance verification would be performed during re-inspection of the said Facility in the next review cycle.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

